Eli Lilly’s oral GLP-1 obesity drug Foundayo (orforglipron) cleared a key heart-safety hurdle in people with diabetes, meeting non-inferiority versus insulin glargine in a cardiovascular outcomes study while showing no greater risk of liver harm. The company also signaled plans to submit Foundayo for FDA review in diabetes by the end of the second quarter under a National Priority Review Voucher.